{"filing":{"accession_number":"0001477449-26-000046","cik":"0001477449","ticker":"TDOC","company_name":"Teladoc Health, Inc.","form":"8-K","filing_date":"2026-09-25","report_date":"2026-09-24","primary_document":"tdoc-20260924.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1477449/000147744926000046/tdoc-20260924.htm"},"events":[{"id":35035,"run_id":32264,"accession_number":"0001477449-26-000046","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.85,"summary":"Adam C. Vandervoort, Chief Legal Officer and Secretary, resigned effective November 1, 2026, with good reason under his severance agreement. While the filing also discloses Jonathan Dorfman's appointment as successor CLO, the principal disclosed action centers on Vandervoort's departure—a named executive officer leaving his role. The departure of a C-suite officer is material to investors assessing management stability and governance.","company_name":"Teladoc Health, Inc.","ticker":"TDOC","filing_date":"2026-09-25","form":"8-K","submitted_at":null,"items":[{"id":38956,"accession_number":"0001477449-26-000046","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"Adam C. Vandervoort, Chief Legal Officer and Secretary, resigned effective November 1, 2026, with good reason under his severance agreement. While the filing also discloses Jonathan Dorfman's appointment as successor CLO, the principal disclosed action centers on Vandervoort's departure—a named executive officer leaving his role. The departure of a C-suite officer is material to investors assessing management stability and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-25T12:31:45.488709+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":38956,"accession_number":"0001477449-26-000046","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"Adam C. Vandervoort, Chief Legal Officer and Secretary, resigned effective November 1, 2026, with good reason under his severance agreement. While the filing also discloses Jonathan Dorfman's appointment as successor CLO, the principal disclosed action centers on Vandervoort's departure—a named executive officer leaving his role. The departure of a C-suite officer is material to investors assessing management stability and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-25T12:31:45.488709+00:00","company_name":"Teladoc Health, Inc.","ticker":"TDOC","filing_date":"2026-09-25"}]}